Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension

Journal of Cardiovascular Pharmacology

Volumn 45, Issue 6, 2005, Pages 599-604

  Derosa, Giuseppe ^a   Cicero, Arrigo E G ^b   Gaddi, Antonio ^b   Mugellini, Amedeo ^a   Ciccarelli, Leonardina ^a   Fogari, Roberta ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Diabetes mellitus; Hypertension; Insulin sensitivity; Lipids

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; HEMOGLOBIN A1C; IRBESARTAN; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INDIVIDUALIZATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADULT; ANALYSIS OF VARIANCE; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DOXAZOSIN; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES;

EID: 19544362031     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000161403.91456.39     Document Type: Article

References (36)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA. 2002;287: 2570-2581.
2. Taskinen MR. Controlling lipid levels in diabetes. Acta Diabetol. 2002; 39(Suppl 2):29-34.
3. Vivian EM, Rubinstein GB. Pharmacologic management of diabetic nephropathy. Clin Ther. 2002;24:1741-1756.
4. Expert Panel on Detection. Evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA. 2001;285:2486-2497.
5. Hernandez-Hernandez R, Sosa-Canache B, Velasco M, et al. Angiotensin II receptor antagonists role in arterial hypertension. J Hum Hypertens. 2002;16(Suppl 1):93-99.
6. Gradman AH. AT(1)-receptor blockers: differences that matter. J Hum Hypertens. 2002; 16(Suppl 3):9-16.
7. Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother. 1998;32:1060-1066.
8. Sica DA, Bakris GL. Type 2 diabetes: RENAAL and IDNT-the emergence of new treatment options. J Clin Hypertens. 2002;4:52-57.
9. Glanz M, Garber AJ, Mancia G, et al. Meta-analysis of studies using selective alpha 1-blockers in patients with hypertension and type 2 diabetes. Int J Clin Pract. 2001;55:694-701.
10. Andersen P, Seljeflot I, Herzog A, et al. Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men. J Cardiovasc Pharmacol. 1998;31:677-683.
11. Inoue Y, Kaku K, Kaneko T, et al. Antihypertensive and metabolic effects of doxazosin in hypertensive patients with concomitant non-insulin-dependent diabetes mellitus. J Int Med Res. 1996;24:138-146.
12. Andersson PE, Lithell H. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow. Am J Hypertens. 1996;9:323-333.
13. The ALLHAT officers and coordinators. For the ALLHAT collaborative research group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlortalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
14. Sica DA. Doxazosin and congestive heart failure. Congest Heart Fail. 2002;8:178-184.
15. American Diabetes Association. Screening for diabetes (position statement). Diabetes Care. 2001;24(Suppl 1):21-24.
16. World Health Organization-International Society. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens. 1999;17:151-183.
17. Mogensen CE, Keane WF. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346:1080-1084.
18. Steiness IB. Vibratory perception in diabetics during arrested blood flow to the limb. Acta Med Scand. 1959;163:195-205.
19. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabetes Med. 1999;16:716-730.
20. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia. 1972;8:260-266.
21. Bunn HF, Gabbay HK, Gallop PM. The glycosylation of hemoglobin. Relevance to diabetes mellitus. Science. 1978;200:21-27.
22. Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem. 1978;15:121-130.
23. nd English ed. New York: Academic Press, 1974:18-31.
24. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1353.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
26. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
27. ESH-ESC Guidelines Committee. 2003 Guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
28. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
29. Man in't Veld AJ. Clinical overview of irbesartan: expanding the therapeutic window in hypertension. J Hypertens Suppl. 1997;15:S27-S33.
30. Derosa G, Cicero AFG, Mugellini A, et al. Perindopril and candesartan comparative efficacy and safety in type 2 diabetic hypertensive patients. J Hum Hypertens. 2003;17:433-435.
31. Higashiura K, Ura N, Miyazaki Y, et al. Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and presser mechanisms in essential hypertension. J Hum Hypertens. 1999; 13(Suppl 1): S71-S74.
32. Ishimitsu T, Yagi S, Sugishita Y, et al. Long-term effects of doxazosin, an alpha 1-blocker, on serum lipids in hypertensive patients. Hypertens Res. 1996; 19:43-49.
33. Daae LN, Westlie L. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. Blood Press. 1998;7: 39-45.
34. Hirano T, Yoshino G, Kashiwazaki K, et al. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. Am J Hypertens. 2001;14:908-913.
35. Kinoshita M, Shimazu N, Fujita M, et al. Doxazosin, an alpha 1-adrenergic antihypertensive agent, decreases serum oxidized LDL. Am J Hypertens. 2001;14:267-270.
36. Agabiti-Rosei E, Giovannini E, Mancia G, et al. Arterial hypertension and heart diseases. Diagnostic-therapeutic guidelines. Joint Commission of the National Association of Hospital Cardiologists, the Italian Society of Cardiology and the Italian Society of Arterial Hypertension. Cardiologia. 1999;44:299-312.